Jun 20, 2019 - Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jun 20, 2019 - Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
Jun 18, 2019 - Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Jun 14, 2019 - Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
Jun 14, 2019 - These big pharma stocks all have a Zacks Rank #2 or better.
Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Jun 13, 2019 - Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.